Advanced Infusion Therapies Delivered with Safety, Expertise, and Care.

Nulojix® (Belatacept) IV Infusion Therapy

Immunosuppressive Therapy for Kidney Transplant Recipients

Clearwell Infusion Centers offers safe, efficient administration of Nulojix (belatacept) infusions for kidney transplant recipients. Located in Miami, our center provides private suites, flexible scheduling, and attentive care to support patients through long-term immunosuppressive therapy.

What Is Nulojix?

Nulojix® (belatacept) is an FDA-approved biologic medication used to prevent organ rejection in adult patients who have received a kidney transplant. It is typically used in combination with other immunosuppressants like mycophenolate and corticosteroids.

Nulojix works by blocking a key pathway (CD80/CD86 and CD28) that activates T-cells, the immune cells responsible for rejecting transplanted organs.

Nulojix is administered via IV infusion initially more frequently, then every 4 weeks on an ongoing basis.

Learn more at the official Nulojix website.

Who Should Receive Nulojix?

Nulojix is indicated for:

  • Adults who have received a kidney transplant
  • Epstein-Barr virus (EBV) seropositive patients only
  • Individuals for whom calcineurin inhibitors may be less desirable

Your transplant team will determine if Nulojix is appropriate based on lab testing and your immunologic risk profile.

Nulojix Side Effects

Common side effects of Nulojix include:

  • Anemia
  • Diarrhea
  • Urinary tract infections
  • High blood pressure
  • Headache
  • Peripheral edema

More serious risks include post-transplant lymphoproliferative disorder (PTLD) and progressive multifocal leukoencephalopathy (PML), which are rare but require close monitoring.

Clearwell’s infusion nurses follow strict ACHC-accredited protocols to monitor for infusion reactions and ensure patient safety.

For full safety details, see the Nulojix prescribing information.

Why Choose Clearwell for Your Nulojix Infusion?

At Clearwell Infusion Centers, we support transplant patients with high-quality, personalized care. When you receive Nulojix therapy at our Miami location, you’ll benefit from:

  • Private treatment suites with spa-like amenities
  • Low patient-to-nurse ratio for attentive care
  • Flexible appointment times, including weekends and evenings
  • Comprehensive insurance coordination, including prior authorizations and benefits checks
  • ACHC-accredited facility and safety standards
  • Close coordination with your prescribing provider and care team

We work closely with your care team to ensure treatment is delivered safely and on schedule.

Getting Started with Nulojix Therapy

If you’ve been prescribed Nulojix, we’ll partner with your transplant physician or nephrologist to begin treatment. Our team manages insurance approvals, coordinates lab and appointment schedules, and helps you stay on track with ongoing therapy.

Questions? Call us at 305‑306‑7147 or email contact@clearwellinfusion.com.

Referring Providers: Partner with Clearwell Infusion Centers

Clearwell Infusion Centers partners with transplant programs, nephrologists, and specialty providers to deliver Nulojix in a monitored outpatient setting.

Why refer your patients to Clearwell?

  • Fast referral process and insurance support
  • Same-week scheduling to maintain adherence
  • Documentation and follow-up reports sent to your office
  • Protocol-driven infusion monitoring
  • ACHC-accredited standards for safety and infection control

To refer a patient for Nulojix infusion therapy in Miami, contact our provider team at referrals@clearwellinfusion.com or call 305‑306‑7147.

Nulojix® (belatacept) logo and label, indicating it is a 250 mg lyophilized powder for injection, intended for intravenous use.

Looking to start your Nulojix treatment at Clearwell Infusion Centers?

Fill out the form below and a member of our team will contact you

Go back

Your message has been sent and a member of our team will contact you. You can call us at (305)306-7147

Warning
Warning
Warning
Warning
Warning
Warning
Warning.